Bone marrow transplantation is divided into autologous bone marrow transplantation and allogeneic bone marrow transplantation.
Autologous bone marrow transplantation is that patients get CR (complete remission) after induction chemotherapy, and then after several courses of consolidation chemotherapy to further reduce the load of tumor cells in the body, some of their own bone marrow is taken out and stored in cold storage, and after ultra-large dose of radical chemotherapy and/or radiotherapy, the preserved bone marrow is transplanted (returned to the patient) to rebuild hematopoiesis.
Advantages:
(1) Difficulties in the source of non-donor.
(2) There is no danger of GVHD.
(3) It is not limited by age, as long as all organs of the body function normally.
Disadvantages: The recurrence rate is higher than that of allogeneic transplantation.
Allogeneic bone marrow transplantation must have HLA (same antigen gene) matched siblings to donate marrow. Only about10% of patients have the opportunity to receive allogeneic bone marrow transplantation, so there are too few opportunities for this method.
Advantages: It is the most effective method for radical treatment of malignant tumor.
Disadvantages: the source of marrow donors is difficult.
Leukemia, commonly known as hematologic cancer, has not been clearly defined at present. Because of its short survival period and high mortality rate, leukemia has posed a great threat to people's health.
2. Diseases treated by bone marrow transplantation:
Leukemia can be divided into acute and chronic. Acute patients have acute onset and short course of disease, and the clinical manifestations are four major symptoms: bleeding, anemia, infection (fever) and infiltration (caused by the deposition of leukemia cells in various tissues, such as liver and spleen, large lymph nodes and bone pain). Without treatment, the survival period is generally less than half a year. Even some cases from diagnosis to death, only a week or so, the main causes of death are bleeding and infection. Chronic patients have hidden onset and generally have no characteristic symptoms. They are often found when their spleen is enlarged due to physical examination or abnormal blood routine examination due to other diseases. If the course of the disease is more than half a year, after proper treatment, the survival time is generally 39-47 months, and the 5-year survival rate is 25%-50%. Some chronic lymphoblastic leukemia can survive for10-20 years, and the causes of death are acute degeneration and bone marrow failure. At present, chemotherapy is the main treatment for leukemia. With the continuous updating of chemotherapy schemes and drugs, its survival time has been significantly prolonged.
Bone marrow transplantation refers to the process of transplanting healthy people or their own remission bone marrow to patients after a large number of leukemia cells are destroyed by high-dose chemotherapy and whole-body irradiation, so that hematopoietic stem cells can differentiate and proliferate in the bone marrow cavity of patients for a long time, thus restoring their normal hematopoietic and immune functions. It can kill leukemia cells to the maximum extent, and it can also save the damage of high-dose chemotherapy and radiotherapy to normal hematopoietic cells. Bone marrow transplantation is the most advanced method to cure leukemia at present. Some patients are eager to have bone marrow transplantation as soon as they find leukemia, which is a wrong view. It can only be done after being completely relieved by active treatment (no symptoms and signs caused by leukemia in clinic, normal hemogram and leukemia cells in bone marrow ≤5%). It can be divided into autologous transplantation and allogeneic transplantation, and the latter can be divided into homologous genes (identical twins) and allogeneic genes (siblings, sisters or parents or children with the same HLA). The specific adaptation conditions are: age: autologous < 55 years old, allogeneic < 45 years old, after leukemia is completely relieved; No infection focus, no other serious diseases; Before allogeneic bone marrow transplantation, tissue matching and related experiments are needed to select donors.
After autologous bone marrow transplantation, because there may still be leukemia cells in bone marrow, intermittent chemotherapy and regular review are needed to prevent recurrence. Bone marrow transplantation has no influence on the donor's health. With the continuous improvement of bone marrow transplantation methods, the long-term survival of leukemia patients needs to be realized. Allograft is risky because of graft rejection and graft-versus-host reaction, but once it is successful, its effect is better than autologous transplantation. Therefore, after leukemia is completely relieved, transplantation should be done as soon as possible.
3, the curative effect of bone marrow transplantation
Many patients want to know the curative effect of bone marrow transplantation in treating malignant hematological diseases, and ask about allogeneic bone marrow transplantation and autologous bone marrow transplantation, especially want to know the curative effect and prognosis of allogeneic bone marrow transplantation and autologous bone marrow (stem cell) transplantation. The relevant chapters about the curative effect of allogeneic bone marrow transplantation and autologous hematopoietic stem cell transplantation in treating various malignant hematological diseases are specially extracted for patients' reference.
Therapeutic effect of allogeneic bone marrow transplantation
The advantages of bone marrow transplantation over ordinary chemotherapy are fully reflected in acute leukemia, and this therapy can significantly improve the disease-free survival rate of patients with acute leukemia. According to the analysis of a large number of cases by Fred Hutchinson Cancer Research Center and IBMTR, the 3-year disease-free survival rate of AML can reach about 50% after receiving ALLo-BMT for the first remission. The 3-year disease-free survival rate of patients undergoing chemotherapy at the same time is only18-27%. The curative effect of BMT is influenced by many factors, mainly including:
1.timing of BMT: the first remission of BMT is better than the second remission. Brotint et AL. (1988) compared the results of BMT in Al patients in the first remission period and the second suspension period, and found that the 5-year recurrence rate of patients after BMT in the first remission period was 21%1%,and the 5-year disease-free survival rate was 46% 9%. The 5-year recurrence rate and survival rate of patients after BMT in the second remission stage were 56% and 22%, respectively. The data of IBMTR and Seattle have similar results. Therefore, patients with acute leukemia should enter BMT in the first complete remission period.
2. The nature of the disease itself: the relationship between the curative effect of BMT and the classification is not clear, and it seems that the curative effect of AML is better than that of ALL. For ALL patients, the following indicators can be considered as high risk factors: (1) The age is less than 2 years old or older than 15 years old, and the peripheral white blood cells at the time of initial diagnosis are more than 50×109/L; (2) Central nervous system leukemia; (3)T cell type or ALL with special cytogenetic changes; (4) For AML patients, the white blood cell count at the initial diagnosis is > 75×109/L, or patients with M4 and M5 have poor prognosis.
3. Patient's age and general situation: The older the patient is, the worse the organ function is, and the greater the possibility of various complications, especially GVHD, after BMT. Therefore, allogeneic bone marrow transplantation should be cautious for patients over 45 years old, and generally no allogeneic bone marrow transplantation should be carried out for patients over 50 years old.
Allogeneic bone marrow transplantation (BMT) is the only way to cure chronic myeloid leukemia at present. After receiving allogeneic bone marrow transplantation, the five-year disease-free survival rate of CML patients in chronic stage can reach 60-90%. Even in the same chronic phase, BMT within 17 months after diagnosis is better than BMT after 17 months. The younger the patient is, the better the curative effect is, and the curative effect of taking hydroxyurea before transplantation is better than that of taking busulfan. The domestic statistical results show that the long-term disease-free survival rate of CML patients in chronic stage is 80% after receiving sibling allogeneic bone marrow transplantation with the same HLA matching, and the allogeneic efficacy of CML patients in accelerated stage or acute stage is not as good as that of chronic stage patients.
In the past, it was considered that MM patients were not suitable for BMT. With the progress of supportive treatment and the emergence of young patients, the number of successful cases of BMT for MM has gradually increased. According to the data of IBMTR, European Bone Marrow Transplantation Office and Ferd Hutchsin Cancer Research Center, about * * * about 150 MM patients worldwide received bone marrow transplantation, and the disease-free survival rate of those who received BMT in the first remission period reached 69%.
BMT treatment of MDS can make the 3-year disease-free survival rate of patients close to 50%, and a considerable part of them can be cured, especially for young patients who receive BMT at an early stage.
Among non-neoplastic diseases, BMT is the most accepted disease. If the patient has not received blood transfusion, the long-term survival rate can reach 80%.
Hereditary immunodeficiency disease, thalassemia, etc.
4. Clinical efficacy of autologous bone marrow transplantation (ABMT)
(1) Acute leukemia
Although allogeneic transplantation has a good effect on acute leukemia, most patients are limited by the lack of suitable donors and high transplant costs. Autologous bone marrow transplantation, as an alternative treatment of allogeneic transplantation, has developed rapidly in recent 10 years. At present, although a lot of clinical data have been accumulated, the position of autologous bone marrow transplantation in the treatment of acute leukemia is still controversial because of the far difference in curative effects reported by various families. Taking acute lymphoblastic leukemia as an example, the long-term leukemia-free survival rate (LFS) of autologous bone marrow transplantation in the first complete remission period ranges from less than 30% to more than 70%. Some data show that autologous bone marrow transplantation does not improve LFS in patients with acute lymphoblastic leukemia, but there are also data that the curative effect of autologous bone marrow transplantation on acute lymphoblastic leukemia with complete remission for the first time is close to that of allogeneic bone marrow transplantation and far superior to that of chemotherapy alone. A similar situation exists in acute myeloid leukemia. Lowebery et al. reported that 32 cases of acute myeloid leukemia were treated with non-purified autologous bone marrow transplantation in the first remission stage, and the 3-year recurrence-free survival rate was only 35%, while Italian scholars also treated 55 cases of acute myeloid leukemia with non-purified autologous bone marrow transplantation in the first remission stage, and the 8-year survival rate was 49% higher, which was not significantly different from that of 104 cases of allogeneic bone marrow transplantation (52%) in the same period. Recently, Memet and others reported the results of their prospective comparative study on the treatment of acute leukemia with chemotherapy or autologous bone marrow transplantation: the LFS of autologous bone marrow transplantation and chemotherapy for more than 3 years in acute myeloid leukemia group were 55% and 34%, respectively, and that of acute lymphoblastic leukemia group was 48% and 22%. This shows that the curative effect of transplantation is better than that of single transplantation
Chemotherapy group. Cahn et al. counted11/cases of acute myeloid leukemia patients over 50 years old who received autologous bone marrow transplantation during the first complete remission, and their 4-year LFS was 34% 5%; Although it is not as good as similar patients under 50 years old, it is better than chemotherapy, so it is advocated that patients over 50 years old should also consider autologous bone marrow transplantation after complete remission. There is such a great difference in the curative effect of autologous bone marrow transplantation on acute leukemia in the literature, which is mainly due to the differences in the patients' condition, chemotherapy before transplantation, pretreatment scheme and supporting treatment conditions, and the lack of representativeness of the cases treated by each family. The curative effect of European Autologous Bone Marrow Transplantation Registry 1992 (see the table below) is due to a large number of cases, which can represent the objective curative effect of autologous bone marrow transplantation from various transplant units. This effect is slightly lower than the 5-year LFS (52% 4% in acute myeloid leukemia group and 50% 5% in acute lymphoblastic leukemia group) of allogeneic bone marrow transplantation in 1993 international bone marrow transplantation registry, but the LFS of patients in the second remission period is the same.
Therapeutic effect of autologous bone marrow transplantation on acute leukemia (1992)
The number of cases of leukemia at the time of classification and transplantation is 8 years LFS
AML standard risk Cr169241%3%
High risk Cr1264 44% 3%
CR2 305 33％±3%
ALL standard risk Cr1280 42% 3%
High risk Cr1174 40% 4%
CR2 357 3 1％±3%
At present, most scholars argue that acute lymphoblastic leukemia with good prognosis does not need autologous bone marrow transplantation in the first complete remission stage, but it is better for high-risk acute lymphoblastic leukemia to undergo autologous transplantation without recurrence after complete remission. Once acute lymphoblastic leukemia recurs, the long-term survival rate of chemotherapy alone is very low after the second remission, while autologous bone marrow transplantation can make 1/3 patients have a long-term survival. There is a group of reports that the LFS of children with acute lymphoblastic leukemia in remission for the first time is 8 1% 3 years after autologous bone marrow transplantation, while that of children with acute lymphoblastic leukemia in remission for less than 2 years is only about 10%. Maintenance therapy for patients at high risk of recurrence after transplantation may be beneficial to reduce recurrence. As for when to carry out autologous bone marrow transplantation for acute myeloid leukemia, most people think that autologous bone marrow transplantation should be carried out in the first complete remission period except for a few subtypes with better chemotherapy effect, such as M3. The transplantation center in Seattle, USA, collected marrow for cryopreservation in the first remission stage of acute myeloid leukemia. Once the patient showed signs of recurrence, it was immediately pretreated with a regimen containing busulfan, and then the previously frozen bone marrow was reinfused. The recurrence-free survival rate (RFS) was about 40%. Patients with acute myeloid leukemia who have achieved the second complete remission should lose no time in autologous bone marrow transplantation.
What is the prospect of autologous bone marrow transplantation to cure acute leukemia? In order to answer this question, the European Bone Marrow Transplantation Collaborative Group specially counted the LFS and recurrence rate of patients with autologous bone marrow transplantation who had not relapsed for 2 years after transplantation during1979-1999. The results are shown in the table below. These data show that those who do not relapse within 2 years after transplantation, although a few patients will relapse later, most patients may have been cured.
The prospect of no recurrence after autologous bone marrow transplantation for 2 years
The recurrence rate of LFS(%) at the time of leukemia type transplantation (%) at the latest recurrence (year)
AML CR 1 77 14 6
CR 2-3 84 12 5. 1
ALL CR 1 84 15 5.3
CR2-3 79 19 4.9
The above table is the statistical data of European bone marrow transplantation collaboration group
(II) Chronic myeloid leukemia
Autologous bone marrow transplantation is not effective for chronic granulocytic leukemia, and allogeneic bone marrow transplantation is the best choice.
Autologous bone marrow transplantation has a good therapeutic effect on malignant lymphoma, so it has become an indispensable treatment for malignant lymphoma. According to statistics, 3399 cases of autologous bone marrow transplantation were performed in 26 European countries in 1992, among which malignant lymphoma 1394 cases were the first of all diseases. Only 123 cases of lymphoma were treated by allogeneic bone marrow transplantation in the same period. The number of malignant lymphoma (Hodgkin's 652 cases, non-Hodgkin's lymphoma 14 17 cases) in 5492 cases of autologous bone marrow transplantation in North America during the period of1992-1993 is also more than other diseases such as leukemia.
Most Hodgkin's disease can be completely relieved or even cured by first-line routine treatment, but there are still 20-50% patients who can't get complete remission or relapse after remission. Without effective treatment, the prognosis of such patients is very poor. After relapse, the survival rate of the first-line treatment scheme (such as MOPP) is generally less than 1 0-20%, and the first complete remission1year or more is slightly better. The curative effect of radiotherapy or non-cross-resistant regimen is also limited, and the 5-year disease-free survival rate (DFS) is less than10%. The general treatment method is even worse for patients with repeated recurrence and drug resistance. High dose chemotherapy plus autologous bone marrow transplantation can significantly improve the long-term survival rate. Chopra et al. used EAMB to pretreat autologous bone marrow transplantation to treat 55 patients with poor prognosis (including 46 cases of primary drug resistance, 7 cases of partial remission, 52 cases of relapse within 1 year, 37 cases of second relapse, and 3 cases of third relapse). Results The transplant-related mortality was10. Peece et al. treated 58 cases of HD with first relapse with general chemotherapy for two courses, and then pretreated with CBV± cisplatin. The median follow-up after autologous bone marrow transplantation was 2.3 years, and PFS was 64%. Systemic symptoms, extranodal diseases or complete remission period less than 1 year at the time of recurrence are unfavorable prognostic factors: 3-year PFS of patients with none, one, two and three items are 100%,8 1%,40% and 0% respectively. In addition, the tumor mass >: 10cm, the prognosis of patients who have been treated for more than three lines is also poor. In order to further prove that autologous bone marrow transplantation is superior to the common treatment scheme, British scholars have conducted a group study on 40 cases of relapsed and refractory HD; 20 cases were treated with ordinary dose EAMB, and the other 20 cases were treated with EAMB.
High dose BEAM and autologous bone marrow transplantation were used. Results The 3-year disease-free survival rate was 53% in transplantation group and only 10% in non-transplantation group, with significant difference between the two groups.
At present, it is still controversial whether the first-time recurrent HD should be treated with autologous bone marrow transplantation immediately, but Armitage is equal to 1994. As the curative effect of autologous bone marrow transplantation in treating recurrent HD is better than that of ordinary chemotherapy, and the related mortality rate of autologous bone marrow transplantation has dropped below 10%, once HD recurs, it should be treated with large dose chemotherapy plus autologous bone marrow transplantation regardless of the length of the first complete remission period.
Although the effective rate of non-Hodgkin's lymphoma (NHL) patients with poor response to first-line treatment or recurrence of moderate and high malignancy NHL can reach 20-60% with common treatment scheme, it is rare for them to achieve lasting remission. Gale et al. pointed out that there are more than a thousand such patients in the literature, and their 2-year survival rate is <: 5%, autologous bone marrow transplantation can significantly improve the long-term survival rate of such patients. The curative effect is related to the tumor condition during transplantation. At the end of 1980s, the European Autologous Bone Marrow Transplantation Registry counted the DFS of 596 NHL patients after transplantation: DFS in the first complete remission, second remission, non-drug resistance recurrence, drug resistance recurrence and primary drug resistance were 67%, 47%, 29%, 17% and 18% respectively. The results reported by Sloan-kettering Hospital in the United States are similar to those of the above multi-centers. The DFS of complete remission, partial remission and disease progression at transplantation are 70%, 62% and 13% respectively. Because the long-term survival rate of patients with drug resistance recurrence is poor, it is generally agreed that NHL that has only achieved partial remission or recurrence in conventional treatment should be treated with autologous bone marrow transplantation in time, and should not be delayed until drug resistance occurs. At present, there is not complete agreement on whether autologous bone marrow transplantation should be done in the first complete remission stage for moderate and high malignant NHL. Many scholars tend to do autologous bone marrow transplantation (ABMT) as early as possible for high-risk NHL with adverse prognostic factors. Freedman et al. recently reported relevant research. * * * Stage Ⅲ-Ⅳ diffuse B-cell NHL with moderate and high malignancy was selected. After induction chemotherapy, 16 cases were completely relieved, 10 cases were partially relieved, and were pretreated with whole body irradiation and cyclophosphamide. As a result, there was no transplant-related death, no treatment was given after transplantation, 2/kloc-0 cases were completely relieved for a long time, 3 cases recurred in the original site, and 2 cases were in the hospital.
Death in solution. At 28 months, DFS was as high as 85%. The authors believe that autologous bone marrow transplantation as a consolidation therapy for NHL with high risk of recurrence can obviously improve the long-term survival rate of such patients after complete remission. The Spanish lymphoma cooperative group reported that 46 cases of NHL underwent autologous bone marrow transplantation in the first complete remission stage, and the DFS reached 75% in 8 years, and the recurrence rate was only 15%. Patients in the first complete remission stage are generally in good condition, so the transplant-related mortality rate is significantly lower than that of advanced patients, and the recurrence rate after transplantation is also low because the tumor cells are not drug-resistant. The prognostic factors of moderate and high malignant NHL are tumor mass >: 10cm, lactate dehydrogenase higher than normal, more than the second remission, drug resistance, etc., but there was no significant difference in tissue type.
The course of most low-grade NHL is as long as 7-10 years, so autologous bone marrow transplantation is seldom used. However, if the complete remission or partial remission period is shorter than 1 year, the median survival time is only 2.4 years, and the prognosis of those who transform to moderate or high malignancy is even worse. Scholars have begun to explore the use of autologous bone marrow to treat low-grade NHL with poor prognosis, but there are few cases, so it is difficult to evaluate its curative effect at present.
The effective rate of general chemotherapy for multiple myeloma is about 50%, but the complete remission rate is less than 10%, and the median survival time is about 3 years. Although allogeneic bone marrow transplantation can cure the disease, few patients can be injected with allogeneic bone marrow transplantation because of the age of the disease at the time of onset. McElwain et al. found that high-dose melphalan can improve the curative effect of multiple myeloma in 1980s, but because of the long bone marrow suppression period, the treatment-related mortality is high. After that, they adopted autologous bone marrow transplantation, that is, the patients were treated with VAMP (vincristine, doxorubicin, methylprednisolone) for several courses to reduce myeloma cells. After the above treatment, the number of tumor cells in bone marrow decreased to less than 30% in 28 of 50 cases (24 cases <: 10%,4 cases 10-20%), the pulp was collected and preserved, and then pretreated with melphalan 200mg/m2. Results The complete remission rate after transplantation was 84%. Barlogie et al. recently reviewed the recent literature including their own work. Among 57 cases of multiple myeloma, 389 cases were autologous bone marrow transplantation. The complete remission rate was 25-35% after transplantation with cyclophosphamide or melphalan 140mg/m2 plus whole body irradiation, and about 70% after pretreatment with melphalan 200mg/m2. A second transplantation within 6-12 months after the first transplantation can further improve the curative effect. Transplantation of peripheral blood stem cells has the advantage of rapid hematopoietic recovery. Some people used melphalan 200mg/m2 for the first transplant and melphalan 140mg/m2 plus whole body irradiation 10Gy for the second transplant. In 15 cases, 1 1 case got continuous complete remission, 5 cases were detected by PCR to detect whether there was minimal residual disease, and 4 cases were the first time.
It was still negative 33 months after transplantation. The results are encouraging and worth further study.
First, acute leukemia
Second, chronic myeloid leukemia
Third, malignant lymphoma:
Four, multiple myeloma:
Five, myelodysplastic syndrome (MDS)
Six, severe aplastic anemia (SAA)
VII. Others:
First, leukemia
Second, malignant lymphoma
Third, multiple myeloma
Fourth, non-hematopoietic system tumors
(1) Hodgkin's lymphoma (HD)
(II) Non-Hodgkin's lymphoma (NHL)
Bone marrow transplantation violates the laws of physiology and nature
Bone marrow transplantation is an advanced therapy initiated by modern international orthodox medicine, but its curative effect is very poor. This therapy can basically be said to be a failure, because life not only has its body, but also has a super-physical, super-material heart and spirit. Life is a small world, a "whole-body embryo" of the universe; Physiology originates from the origin of life and the evolution process of hundreds of millions of years. It is closely related to nature and follows the universal causal natural law. Therefore, the mystery of life is super-machine, which can't be dominated by any "macro" or "micro" scientific research achievements. We can't treat diseases as mechanical repair and loading and unloading, and we can't design and calculate dialectical treatment as a construction project.
Destroyed the immunity of life
The biggest mistake of bone marrow transplantation is that in the process of transplantation, it destroys the immunity and self-reliance function of life, making it unable to play the role of "rejection", and the transplantation is successful. However, immunity is an important factor for life to survive by self-defense, and the basic pillar for its development and growth. The destruction of immunity means that the roots of trees have been broken, and no life can live normally.
Matching difficulty
Another important defect of bone marrow transplantation is that there are few bone marrow donors suitable for transplantation, because it is very difficult to find bone marrow suppliers with the same HLA match. According to statistics, it only accounts for about 2/100,000 of the masses, that is, about 2 out of 100,000 people; Moreover, even if people with the same match are found, they are often reluctant to supply because they are worried about the damage to the body after pulp extraction.
Autologous bone marrow transplantation is also a waste of energy.
Autologous bone marrow transplantation, which is initiated by the medical community, is not limited by the source of donors, but this treatment is not only a waste of energy, but also a serious violation of physiological laws. Because the patient's bone marrow is a lesion, the so-called immature cells are a local phenomenon of the patient's overall disease, and they are a symptom, not the source and pathogen. Even if the remaining immature cells are cleaned up, the patient's overall situation has not been improved, and the bone marrow adopted is some lifeless tissues, how can it have the function of radically curing this disease?
The success rate is extremely low and the cost is extremely high.
In recent years, I have come into contact with many patients with bone marrow transplantation. They have suffered cruel pain, some died because of failed transplantation, some committed suicide in despair, and some succeeded in transplantation, but they soon relapsed. However, the cost of transplantation is staggering. In Chinese mainland, each case needs 200,000 to 300,000 RMB.
The side effects are too great, and the future troubles are endless.
There are still many adverse side effects of bone marrow transplantation that have not been correctly understood by the medical profession, patients, family members and some people in society. I would like to suggest a summary for reference.
The patient's overall deformation, deterioration, metamorphosis, and loss of normal and natural health beauty.
Shortening the life cycle is ignored by the medical community, and it can even be said that it is blind. If a person's life cycle of birth, growth, decline and old age is 80 years on average, when he is 20 years old, he should still have a life limit of 60 years. If he suffers from leukemia, he will be treated with chemotherapy and bone marrow transplantation, even though he has used a lot of protein, hormones and blood to alleviate his survival ... It looks strong on the outside, but his life cycle is greatly shortened, and the remaining 60 years of life resources are saved This is a very serious situation, which must be paid attention to by the relevant authorities.
Loss of life significance: after chemotherapy or marrow implantation, the immunity is destroyed and the function of self-reliance is lost. In order to prevent infection, doctors try to isolate themselves from the outside world, even put them in sterile rooms, and often disinfect, test blood, draw marrow, and conduct various examinations and tests, and often inject nutrients, tonics, and anti-inflammatory agents to maintain their lives. In this way, on the surface, they are given advanced equipment and scientific treatment, but in fact, they are deprived of their lives. If you live here for a long time in pain and ruthlessness like a prisoner, it will completely lose the meaning of being a human being.
Vegetarian therapy for leukemia
Someone asked me how I explained the important role of vegetarianism in treatment. My answer is that life is an "holographic embryo" of nature, that is, a "holographic miniature"; Therefore, human beings living in nature are like babies in their mother's arms, and plants in nature are the most suitable and nutritious food, just like breast milk. Meat not only goes against the physiology and nature, but also breeds toxins. When animals are killed, their bitter resentment will inevitably emit high-frequency and short-wave biological electromagnetic waves to penetrate into various cells and tissues, and it is also a serious mental environmental pollution to space.
Long-term clinical practice, we have observed that almost all patients with leukemia and cancer are partial eaters of meat (animal food). During the treatment, if they can be basically vegetarian, their condition can be obviously improved, thus creating conditions for early recovery. This is the experience and insight of China medical practitioners for thousands of years.
In recent years, I have also made the following explanation for "dietotherapy". The diet of all life in the world can be divided into two categories, namely, plant food (vegetarian food) and animal food (meat). Some lives are mainly vegetarian, such as cattle, horses, sheep, bees, some lives are mainly carnivorous, such as tigers, leopards, wolves, snakes, etc., and some lives are both vegetarian and vegetarian. We should understand that diet is the main raw material of the body, and taking vegetarian food as the raw material will make the body clean and pollution-free; With meat as raw material, the body is bound to be dirty and turbid. Imagine that if your body is built on the corpses of other animals, it will inevitably be seriously polluted, and eventually it will inevitably be riddled with diseases and endless future troubles. For example, diabetes, hypertension, angiosclerosis, stroke, heart disease, gallstones, cholecystitis, hepatitis, gout, gastric ulcer, nephritis, urinary tract infection, kidney calculi's disease, lupus erythematosus, dermatomyositis, as well as many intractable diseases and strange diseases, while leukemia and some cancers, especially meat partisans, are frequently-occurring diseases. We can cite many cases for verification.
The main causes and treatment of leukemia
According to China's medical theory, the so-called leukemia is a viral disease, and it is a complication induced by external causes of physiological disorder. Its main causes are kidney yin deficiency, excessive fire, deep toxic accumulation, qi and blood hurting the disorder of governor, ren and chong, and its main symptoms are frequent fever, anemia, blood stasis and bleeding, hepatosplenomegaly, mouth and tongue ulcer, and frequent soreness of lower limb joints. There are several types of leukemia, and the symptoms of each type are not the same. In the development of this disease, some of the above symptoms may appear one after another. The basis for the diagnosis of this disease by western medicine is that there are many abnormal white blood cells in the patient's bone marrow, that is, naive white blood cells. The treatment of this disease is to tonify kidney yin, astringe fire, clear away heat and toxic materials, turn hard mass into hard mass, and regulate the pulse of Du, Ren and Chong. According to China's medical theory, method, prescription and medicine, the treatment based on differentiation of symptoms and signs is better. The so-called immature cell is a local manifestation of the whole disease, a symptom, not a pathogen and pathogen. We should never cling to killing immature cells with chemotherapy poison, because repeated chemotherapy and strengthening will inevitably lead to ruin and mutual destruction. There have been a large number of cases to verify the therapeutic effect and comparison between traditional Chinese medicine and western medicine.